• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Genetic, environmental risk assessment does not increase colon cancer screening

byNicholas WoolfandSai Folmsbee
October 21, 2014
in Gastroenterology, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients who received genetic and environmental risk assessment (GERA) were not more likely to initiate colorectal cancer (CRC) screening than those who did not.

2. Among patients who received GERA, there was no significant difference in screening between those of elevated versus moderate risk for CRC.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Interactions between genetics and the environment are involved in the development of cancer, and performing risk assessments to examine susceptibility is becoming increasingly popular. However, it is unknown whether these tests could motivate recipients to improve their health behaviors. In this study, patients with average-risk for developing CRC and not adhering to the recommended screening regimen were randomized into groups that received either GERA or usual care. The GERA protocol examined the status of the methylenetetrahydrofolate reductase (MTHFR) gene and serum folate levels, which correlate with a moderate increase in risk for CRC. Although the authors predicted that GERA would encourage those at risk to subsequently follow screening guidelines, there was no significant difference in screening rates at six months post-initial assessment between the GERA and usual care groups. Within the GERA group, patients classified as having a higher risk for CRC did not pursue screening more than patients with average risk. This study was limited in that it assessed the effect of only one out of several possible sets of GERA results on one health behavior (i.e., CRC screening).

Click to read the study in the Annals of Internal Medicine

Relevant Reading: Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: A randomized clinical trial

In-Depth [randomized controlled trial]: In order to be included in the study, patients needed to be between 50-79 years old, at average risk for CRC, initially non-adherent to CRC screening guidelines, off antibiotics or antifolate medications in the past six weeks, and English speaking. Out of the initial group of patients contacted, 783 completed a baseline survey and were randomized into the GERA and usual care intervention groups. Patients in the GERA group met with trained study nurses who collected blood samples for analysis, and results were subsequently given to the patients via telephone and mail. Each participant received questionnaires about CRC screening at three weeks and six months post-enrollment. After adjusting for possible confounders, the authors found that CRC screening rates were similar between groups receiving GERA and usual care (adjusted OR 0.88; 95%CI 0.64-1.22). Among patients receiving GERA, those with an elevated risk for CRC pursued screening at a lower rate than those with an average risk for CRC (adjusted OR 0.75; 95%CI 0.39-1.42).

RELATED REPORTS

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

Ovarian cancer screening does not reduce mortality [Classics Series]

Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.

More from this author: Financial conflicts of interest bias recommendations for influenza meds, USPSTF recommends counseling for patients at high-risk for STIs, USPSTF recommends aspirin for women at risk for preeclampsia, Marked decline in cystic fibrosis-related mortality over 10 years, ACP endorses polysomnography over portable monitors for diagnosing sleep apnea

Image: CC/Nephron

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: cancer screeningcolon cancer
Previous Post

Clinicians frequently unaware of the presence of central venous catheters

Next Post

Dopamine receptor agonists may be associated with impulse control disorders

RelatedReports

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ
Oncology

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

August 19, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Ovarian cancer screening does not reduce mortality [Classics Series]

August 12, 2022
Patient Basics: Colonoscopy
Oncology

Breast, colorectal, and cervical cancer screening was reduced during the COVID-19 pandemic as compared to pre-COVID time periods.

July 18, 2022
Chronic Disease

COVID-19 pandemic associated with reductions in delivery of cancer care services in Ontario, Canada

April 29, 2022
Next Post
Dopamine receptor agonists may be associated with impulse control disorders

Dopamine receptor agonists may be associated with impulse control disorders

Price transparency leads to lower claims payments by patients and insurers

Price transparency leads to lower claims payments by patients and insurers

Gut bacteria respond to daily rhythms and influence weight control

Gut bacteria respond to daily rhythms and influence weight control

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options